Acquisition of new mutations or pre-existing genetic alterations is linked to disease progression in NSCLC patients with EGFR mutations (20–23), and the highly heterogeneous and complex genetic landscape of this type of cancer impacts clinical outcomes. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.